PD-L1 expression, evaluated through immunohistochemistry (IHC), remains the most widely used biomarker for predicting response to PD-1/PD-L1 inhibitors in NSCLC [9]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.